RVL Pharmaceuticals plc Retained Earnings
RVL Pharmaceuticals plc had Retained Earnings of -$604.72 million as of 2023-06-30, per its 10-Q filed 2023-08-14.
Discontinued › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2023-08-14
- 2023-06-30: Retained Earnings (Accumulated Deficit) -$604.72M.
- 2023-03-31: Retained Earnings (Accumulated Deficit) -$580.83M.
- 2022-12-31: Retained Earnings (Accumulated Deficit) -$569.22M.
- 2022-09-30: Retained Earnings (Accumulated Deficit) -$550.90M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2023-06-30 | -$604.72M 10-Q · filed 2023-08-14 | |
| 2023-03-31 | -$580.83M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | -$569.22M 10-Q · filed 2023-08-14 | |
| 2022-09-30 | -$550.90M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | -$536.46M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | -$524.35M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | -$517.53M 10-K · filed 2023-03-20 | |
| 2021-09-30 | -$497.81M 10-Q · filed 2021-11-15 | |
| 2021-06-30 | -$479.95M 10-Q · filed 2021-08-16 | |
| 2021-03-31 | -$462.22M 10-Q · filed 2021-05-13 | |
| 2020-12-31 | -$452.61M 10-K · filed 2022-03-30 | |
| 2020-09-30 | -$397.74M 10-Q · filed 2020-11-10 | |
| 2020-06-30 | -$389.10M 10-Q · filed 2020-08-11 | |
| 2020-03-31 | -$376.10M 10-Q · filed 2020-05-12 | |
| 2019-12-31 | -$373.02M 8-K · filed 2021-09-08 | |
| 2019-09-30 | -$346.38M 10-Q · filed 2019-11-14 | |
| 2019-06-30 | -$233.21M 10-Q · filed 2019-08-08 | |
| 2019-03-31 | -$108.56M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | -$102.12M 10-K · filed 2020-03-19 | -$102.36M 10-K · filed 2019-03-28 |